公开(公告)号：US20240189443A1

公开(公告)日：2024-06-13

申请号：US18550346

申请日：2022-03-15

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Likun GONG ,  Xiaolu YU ,  Yiru LONG ,  Jianhua SUN ,  Yongliang TONG ,  Tingting LIU

IPC: A61K47/68 ,  A61J1/05 ,  A61P35/00 ,  C07K16/28

CPC classification number: A61K47/6849 ,  A61J1/05 ,  A61K47/6803 ,  A61P35/00 ,  C07K16/2827 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/569 ,  C07K2319/30

Abstract: Disclosed in the present invention are a use of a combination of an anti-PD-L1 nanobody and a TLR7 small molecule agonist in anti-tumor treatment, and a PD-L1 and TLR7 double-targeting nanobody coupling drug, a preparation method therefor, and a use thereof. Specifically, disclosed in the present invention are a use and solution of a combination of an anti-PD-L1 nanobody and a derived protein thereof as well as a TLR7 small molecule agonist and a derived compound thereof in anti-tumor treatment. Meanwhile, disclosed in the present invention are design, preparation, and identification solutions for a novel PD-L1 and TLR7 double-targeting-nanobody drug conjugate and a derived molecule thereof, and an effect of the novel PD-L1 and TLR7 double-targeting nanobody drug conjugate in anti-tumor treatment. The PD-L1 and TLR7 double-targeting nanobody drug conjugate of the present invention can yield a significant antineoplastic efficacy in various transplantation tumor models.